Cargando…

The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study

BACKGROUND: Intense statin therapy was found to impair testosterone production in men. Metformin administered to subjects with hypergonadotropic hypogonadism decreased gonadotropin production. The current study was aimed at investigating whether metformin treatment modulates the impact of high-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Krysiak, Robert, Basiak, Marcin, Szkróbka, Witold, Okopień, Bogusław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460565/
https://www.ncbi.nlm.nih.gov/pubmed/34086261
http://dx.doi.org/10.1007/s43440-021-00289-1
_version_ 1784571784222212096
author Krysiak, Robert
Basiak, Marcin
Szkróbka, Witold
Okopień, Bogusław
author_facet Krysiak, Robert
Basiak, Marcin
Szkróbka, Witold
Okopień, Bogusław
author_sort Krysiak, Robert
collection PubMed
description BACKGROUND: Intense statin therapy was found to impair testosterone production in men. Metformin administered to subjects with hypergonadotropic hypogonadism decreased gonadotropin production. The current study was aimed at investigating whether metformin treatment modulates the impact of high-dose rosuvastatin therapy on hypothalamic–pituitary–testicular axis activity in men. METHODS: The study included 43 very high cardiovascular risk men with late-onset hypogonadism, 20 of whom had been treated with metformin (1.7–3 g daily) for at least 6 months. In all subjects, unsuccessful initial statin treatment was replaced with rosuvastatin (20–40 mg daily). Plasma lipid levels, glucose homeostasis markers, as well as circulating levels of gonadotropins, testosterone, bioavailable testosterone, dehydroepiandrosterone-sulfate, prolactin, estradiol and creatinine were measured at the beginning of the study and 4 months later in 28 individuals in whom rosuvastatin reduced LDL cholesterol levels to below 70 mg/dL. RESULTS: There were no differences between treatment-induced changes in plasma lipids. In both study groups, rosuvastatin reduced total and bioavailable testosterone levels. However, only in metformin-naïve men, rosuvastatin increased LH and FSH levels and slightly impaired insulin sensitivity. The impact on gonadotropin concentrations correlated with treatment-induced decrease in testosterone levels. There were no significant differences between baseline and posttreatment values of dehydroepiandrosterone-sulfate, prolactin, estradiol and the glomerular filtration rate. CONCLUSION: The obtained results suggest that metformin prevents the compensatory increase in gonadotrope function induced by intense statin therapy.
format Online
Article
Text
id pubmed-8460565
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-84605652021-10-07 The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study Krysiak, Robert Basiak, Marcin Szkróbka, Witold Okopień, Bogusław Pharmacol Rep Short Communication BACKGROUND: Intense statin therapy was found to impair testosterone production in men. Metformin administered to subjects with hypergonadotropic hypogonadism decreased gonadotropin production. The current study was aimed at investigating whether metformin treatment modulates the impact of high-dose rosuvastatin therapy on hypothalamic–pituitary–testicular axis activity in men. METHODS: The study included 43 very high cardiovascular risk men with late-onset hypogonadism, 20 of whom had been treated with metformin (1.7–3 g daily) for at least 6 months. In all subjects, unsuccessful initial statin treatment was replaced with rosuvastatin (20–40 mg daily). Plasma lipid levels, glucose homeostasis markers, as well as circulating levels of gonadotropins, testosterone, bioavailable testosterone, dehydroepiandrosterone-sulfate, prolactin, estradiol and creatinine were measured at the beginning of the study and 4 months later in 28 individuals in whom rosuvastatin reduced LDL cholesterol levels to below 70 mg/dL. RESULTS: There were no differences between treatment-induced changes in plasma lipids. In both study groups, rosuvastatin reduced total and bioavailable testosterone levels. However, only in metformin-naïve men, rosuvastatin increased LH and FSH levels and slightly impaired insulin sensitivity. The impact on gonadotropin concentrations correlated with treatment-induced decrease in testosterone levels. There were no significant differences between baseline and posttreatment values of dehydroepiandrosterone-sulfate, prolactin, estradiol and the glomerular filtration rate. CONCLUSION: The obtained results suggest that metformin prevents the compensatory increase in gonadotrope function induced by intense statin therapy. Springer International Publishing 2021-06-04 2021 /pmc/articles/PMC8460565/ /pubmed/34086261 http://dx.doi.org/10.1007/s43440-021-00289-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Krysiak, Robert
Basiak, Marcin
Szkróbka, Witold
Okopień, Bogusław
The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
title The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
title_full The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
title_fullStr The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
title_full_unstemmed The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
title_short The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
title_sort impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460565/
https://www.ncbi.nlm.nih.gov/pubmed/34086261
http://dx.doi.org/10.1007/s43440-021-00289-1
work_keys_str_mv AT krysiakrobert theimpactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy
AT basiakmarcin theimpactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy
AT szkrobkawitold theimpactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy
AT okopienbogusław theimpactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy
AT krysiakrobert impactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy
AT basiakmarcin impactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy
AT szkrobkawitold impactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy
AT okopienbogusław impactofrosuvastatinonhypothalamicpituitarytesticularaxisactivityinmetformintreatedandmetforminnaivemenwithlowtestosteronelevelsapilotstudy